BIT's 8th World Congress of Industrial Biotechnology
★ Submission Guideline

1. The organizing committee of ibio-2015 invites all abstracts within the scope of the meeting. Submitted abstracts will be reviewed by experts and scheduled for either poster or oral presentation during the congress. Irrelevant or poor quality abstracts may be rejected.


2. Abstracts shall be submitted to our coordinators by email: amy@bit-ibiocongress.com


3. Abstracts should be written in clear English, please find the attachment for the template, taking in to account the specifications below:

  1. Maximum word count of abstract title is 20 words.


  2. Maximum word count of the abstract text is 350 words (adjust in case of tables/figures)


  3. The abstract topic should be selected during the online submission process from the list of predefined topics in order to facilitate abstract review and scheduling.


  4. A minimum of three specific keywords should be added during online submission for indexing of the abstract. Specific keywords include: name(s) of drug(s) investigated, molecular target molecule(s), disease(s) studied, biochemical or biological function(s) studied. Avoid the use of vague keywords such as: angiogenesis, cell death, cancer, tumor, drug development, drug therapy. The organizing committee of ibio-2014 reserves the right to delete, edit or add keywords in order to achieve uniformity throughout abstract publications.


  5. Use International Nonproprietary Names (INN) or research codes to identify drugs throughout the abstract. Proprietary names may be used in the abstract text, not the title. The first time the drug is mentioned in the text us the INN and put the proprietary name between brackets.


  6. The identity of a new, previously unpublished, drug substance needs to be disclosed in the abstract either by providing its structural formula or full chemical name.

4. Abstracts will be published exactly as submitted. No editing of abstract texts will be done. However, failure to comply with the above guidelines may be corrected (e.g. use of drug names, keywords) by the meeting organizers.


5. After submission abstracts can no longer be changed by the authors. Should minor changes be necessary after submission, the author should notify Ms. Amy Shang by email at amy@bit-ibiocongress.com, describing exactly the nature of the change to be made. The ibio-2015 organizers will then implement the change. If major changes are required the author should submit a revised abstract as an entirely new abstract and send a request to amy@bit-ibiocongress.com to delete the original abstract. The addition of a co-author constitutes a major change.


6. After completion of the abstract review, the submitting author will receive scheduling information via email. Abstracts cannot be withdrawn after receipt of the scheduling information by the submitting author. The presenting author must be registered as a participant of ibio-2015 for final scheduling and publication of the abstract.


7. Accepted abstracts will be published in the Congress Proceedings. The authors of the submitted abstracts are responsible for any Intellectual Property issues concerning the abstracts on their own. The organizing committee of ibio-2015 reserves the right to use submitted abstracts for conference purposes.

Conference Brochure
News Released

• REGISTER NOW to secure your attendance
• Program released already!
• Speaking proposals are now being accepted, submit the abstract right now

Hosting Organizations

China Council for the Promotion of International Trade


Nanjing Municipal Government
Supporting Organization

Information Research Center of International Talent, SAFEA

Operating Organizations

Economic Information Department, China Council for the Promotion of International Trade


Nanjing Economic and Information Commission


The Bureau of the Nanjing Food and Drug Administration


Nanjing Municipal Investment Promotion Commission


Nanjing Municipal Health Bureau


China Council for the Promotion of International Trade, Nanjing Sub-Council



Zhen-Ao Group


BIT Congress Inc.

Official Travel Agency

BIT World Travel Service, Inc.

SkyTeam

Renowned Speakers
Dr. Charlie Xu,
Sr, Director, Clinical Development, BioSciKin Inc, China
Dr. Charles Zhou,
President, Chairman and CEO, Cascade Clean Energy, Inc., USA
Mr. Richard Fish,
President, Alter Nrg Corp., Canada
Dr. Yom-Tov Samia,
President and CEO, IC Green Energy LTD, Israel
Dr. Roland A. Jansen,
CEO, Biomass Partners Ltd.; Director Biomass Investments, Green Investment Solutions Holding PLC, Switzerland
Dr. Paul O'Connor,
Founder, BIOeCON, The Netherlands
Dr. Surajit Khanna,
Chairman and CEO, BARD Holding, Inc, USA
Dr. Jing Liu,
CCo-founder,Owner, CTO, Bioprocess Control AB, Sweden
Dr. Virginia Klausmeier,
CEO and Co-founder, Sylvatex Biofuels, USA
Dr. Salee Amina Mohammed,
Co-owner, Royal Green Bio-Tech; President, Domino Dynamics, USA
Dr. Daniel Siegel,
VP Technology & IP Assessment, FuturaGene, Ltd., Israel
Dr. Xujin Lu,
Senior Principal Scientist, Bristol-Myers Squibb Company, USA
Dr. Silvan de Boer,
Senior Sustainability Officer, Eneco, The Netherlands
Dr. Giulio Tarro,
DPresident, Foundation T. & L. de Beaumont Bonelli for cancer research, Italy
Dr. Ronald Zwart,
Director Biomass Consultancy and Project Development, CKade BV, The Netherlands
Dr. Rajesh C Shrotriya,
Chairman and Chief Executive Officer, Spectrum Pharmaceuticals, Inc., USA
Ms. Vivian Lee,
Managing Director, Aqua Partners LLC, USA
Dr. Ying Ji,
Vice President, Paritic Inc, USA
Dr. Richard Hurding,
CEO, Zelfo Technology GmbH; Owner. Omodo GmbH, Germany
Mr. Rowan Williams,
Regional Market Development Manager - Advocacy, BASF Australia Limited, Australia
Dr. Eyal S Ron,
CTO,Gelesis, USA
Dr. Christophe Reuzeau,
Senior Licensing Manager ASIA Pacific, CropDesign BASF Plant Science, Belgium
Dr. Narender Nehra,
Director, Donald Danforth Plant Science Center, USA
Dr. Dotan Peleg,
CEO, Morflora, Israel
Dr. Henning Trozelli,
Director, Dow AgroSciences LLC, USA
Dr. John Baker,
President, Alan Environmental, LLC, USA
Mr. John Williams,
President & CEO, In-Pipe Technology Company, USA
Dr. Kasiviswanathan Muthukumarappan,
Professor, South Dakota State University, USA
Dr. Donghai Wang,
Professor, Biological and Agricultural Engineering, Kansas State University, USA
Dr. Syed Ubaidullah Hussainy,
Professor, Victoria University, Australia
Dr. Jutta Geldermann,
Professor, Vice-Dean of the Faculty, Georg-August-Universitat Gottingen, Germany
Prof. Dr. Dr. Rolf G. Werner,
Professor Industrial Biotechnology, University of Tuebingen, Germany
Dr. Jamil Baghdachi,
Professor, Eastern Michigan University, USA
Dr. Xiuzhi Susan Sun,
University Distinguished Professor, Kansas State University, USA
Dr. José Kenny,
Professor, University of Perugia, Italy
Dr. Ray T. Chen,
Professor, University of Texas at Austin, USA
Dr. Somenath Mitra,
Professor, New Jersey Institute of Technology, USA
Dr. Pedro Alvarez,
Professor and Chair, Rice University, USA
Dr. Daniel Y.C. Fung,
Professor, Kansas State University, USA
Dr. Dewey D. Y. Ryu,
Professor, University of California, USA
Dr. Xiucai Liu, Founder,
Chairman & CEO, Cathay Industrial Biotech Ltd., China

BIT’s Upcoming Events
Contact Us

Add: East Area, F11, Building 1, Dalian Ascendas IT Park, 1 Hui Xian Yuan, Dalian Hi-tech Industrial Zone, LN 116025, China]
Tel: 0086-411-84799609, Fax: 0086-411-84796897
Copyright © 2014-2015 BIT Congress Inc.